Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica

Neurology

Volumn 81, Issue 8, 2013, Pages 710-713

  Yang, Chun Sheng ^a   Yang, Li ^a   Li, Ting ^a   Zhang, Da Qi ^a   Jin, Wei Na ^a   Li, Min Shu ^a   Su, Ning ^a,b   Zhangning, Nannan ^a   Liu, Qiang ^a,b   Shao, Zong Hong ^a   Yu, Chunshui ^a   Shi, Fu Dong ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; BRAIN; BRAIN DAMAGE; BRAIN FUNCTION; CHINESE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; RELAPSE; RELAPSING LONGITUDINAL EXTENSIVE TRANSVERSE MYELITIS; REPEATED DRUG DOSE; SPINAL CORD; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEUROMYELITIS OPTICA; TREATMENT OUTCOME;

EID: 84884481212     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a1aac7     Document Type: Article

References (10)

1. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012;11:535-544.
2. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17: 1225-1230.
3. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-1272.
4. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012;18:1022-1026.
5. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448.
6. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68:1412-1420.
7. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007;13:2-11.
8. Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:659-663.
9. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-1698.
10. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-437.